Video

Dr. Hoos on a Possible Successor Drug to Ipilimumab

Author(s):

Axel Hoos, MD, PhD

Dr. Axel Hoos Medical Lead in Immunology/Oncology at Bristol-Myers Squibb on a Possible Successor Drug to Ipilimumab

Axel Hoos, MD, PhD, the medical lead in Immunology/Oncology at Bristol-Myers Squibb discusses the multiple immunotherapy agents in development, including the most advanced anti-PD-1 agent MDX-1106 which has a similar mechanism of action to ipilimumab (Yervoy).

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Subscribe Now!

Latest CME

View All
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Jun 6th 2025 - Jul 12th 2025

online-activity
View More
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Jun 6th 2025 - Jul 12th 2025

online-activity
View More
Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing
Video

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Jun 5th 2025 - Jul 12th 2025

online-activity
View More
Related Content
The FDA has approved new options in head and neck cancer, lung cancer, and bladder cancer—and more from OncLive this week.
June 14th 2025

The OncFive: Top Oncology Updates for the Week of 6/8

OncLive On Air
September 11th 2024

Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress

Melanoma | Image Credit: © Cyber Shutter - stock.adobe.com
June 6th 2025

RP1 Yields Responses in Deep/Visceral Lesions and Across Injected/Non-Injected Lesions in Advanced PD-1–Refractory Melanoma

Jeffrey S. Weber, MD, PhD
November 6th 2023

FDA Approval Insights: Adjuvant Nivolumab in Completely Resected Stage IIB/C Melanoma

Adjuvant Encorafenib/Binimetinib in BRAF V600–Mutant Melanoma | Image Credit: © Artur - stock.adobe.com
June 3rd 2025

Adjuvant Encorafenib/Binimetinib Is Well Tolerated and May Reduce Recurrence Risk in BRAF V600–Mutant Melanoma

Cervical Cancer | Image Credit: © freshidea - stock.adobe.com
June 3rd 2025

Exploratory Analysis From CALLA Study Highlights Potential Utility of ctDNA in Locally Advanced Cervical Cancer